HIV Drugs Go Generic

Patent expirations of one HIV drugs will make the disease cheaper—but also more cumbersome—to treat.

By | August 16, 2012

image: HIV Drugs Go Generic Flickr Creative Commons, .v1ctor.

This year, the United States is expected to spend nearly $15 billion on healthcare for HIV patients, which still doesn’t cover all of the patients who need treatment. But those costs are expected to decrease in the next few years as the patents for brand-name antiretrovirals expire.

“AIDS, as we currently know it, may become much more affordable,” John Bartlett, an infectious-disease researcher at Johns Hopkins Bloomberg School of Public Health, told Nature.

The three-in-one antiretroviral Atripla is considered the go-to first line therapy for HIV and is made up of two drugs made by Gilead Sciences and one by Bristol-Myers Squibb (BMS). While only one component from this cocktail, BMS’s efavirenz, will go off patent next year, a second component already has a readily available generic substitute. The cost saving from these two drugs is estimated to save $920 million in the first year.

Although it will be more cumbersome for patients to take three pills per day instead of one, and as a result, they might be more likely to forget or skip doses, most advocates agree that that giving more people access to the medication is worth the trade-off.

Advertisement

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Comments

Avatar of: Angelise Evony

Angelise Evony

Posts: 1457

August 16, 2012

This isn't the big news. The big news is that so much funding is spent to combat a disease that affects a very small niche portion of the population. I guess it's true what they say though, the squeaky wheel gets the most grease. :(

Advertisement
Arbor Assays
Arbor Assays

Popular Now

  1. The Mycobiome
    Features The Mycobiome

    The largely overlooked resident fungal community plays a critical role in human health and disease.

  2. Antibody Alternatives
    Features Antibody Alternatives

    Nucleic acid aptamers and protein scaffolds could change the way researchers study biological processes and treat disease.

  3. Holding Their Ground
    Features Holding Their Ground

    To protect the global food supply, scientists want to understand—and enhance—plants’ natural resistance to pathogens.

  4. Circadian Clock and Aging
    Daily News Circadian Clock and Aging

    Whether a critical circadian clock gene is deleted before or after birth impacts the observed aging-related effects in mice.

Advertisement
Advertisement
Life Technologies